GD2-mediated melanoma cell targeting and cytotoxicity of liposome- entrapped fenretinide

International Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 268-274

  Pagnan, Gabriella ^a   Montaldo, Paolo G ^a   Pastorino, Fabio ^a   Raffaghello, Lizzia ^a   Kirchmeier, Marc ^b   Allen, Theresa M ^b   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; GANGLIOSIDE GD2; IMMUNOLIPOSOME; MACROGOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MELANOMA CELL; NEUROECTODERM TUMOR; PRIORITY JOURNAL; TARGET CELL;

EID: 0032957035     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19990412)81:2<268::aid-ijc17>3.0.co;2-1     Document Type: Article

References (41)

1. AHMAD, I., LONGENECKER, M., SAMUEL, J. and ALLEN, T.M., Antibody-targeted delivery of duxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res., 53, 1484-1488 (1993).
2. ALLEN, T.M., Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci., 15, 215-220 (1994).
3. ALLEN, T.M., AHMAD, I., LOPES DE MENEZES, D.E. and MOASE, E.H., Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans., 23, 1073-1079 (1995a).
4. ALLEN, T.M., BRANDEIS, E., HANSEN, C.B., KAO, G.Y. and ZALIPSKY, S., A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. biophys. Acta, 1237, 99-108 (1995b).
5. ALLEN, T.M., HANSEN, C., MARTIN, F., REDEMANN, C. and YAU-YOUNG, A., Liposomes containing synthetic lipid derivates of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. biophys. Acta, 1066, 29-36 (1991).
6. BALCH, M., HOUGHTON, A. and PETERS, L., Cutaneous melanoma. In: V.T. DeVita, Jr., S. Hellman and S.A. Rosenberg (eds.), Cancer principles and practice of oncology, pp. 1499-1542, Lippincott-Raven, Philadelphia (1989).
7. CLAFFEY, K., BROWN, L., DEL AGUILA, L., TOGNAZZI, K., YEO, K., MANSEAU, E. and DVORAK, H., Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res., 56, 172-181 (1996).
8. FORMELLI, F., BARUA, A.B. and OLSON, J.A., Bioactivities of N-(4-hydroxyphenyl)retinamide and retinol B-glucuronide. FASEB J., 10, 1014-1024 (1996).
9. FORMELLI, F., CLERICI, M., CAMPA, T., DI MAURO, M.G., MAGNI, A., MASCOTTI, G., MOGLIA, D., DE PALO, G. and COSTA, A., Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J. clin. Oncol., 11, 2036-2042 (1993).
10. FORMELLI, F., LUKSCH, R., CAVADINI, E., PONZONI, M., MONTALDO, P.G., FOSSATI, F. and GARAVENTA, A., Phase 1 and pharmacokinetic evaluation of fenretinide in children with advanced neuroblastoma. Amer. Ass. Cancer Res., Abstract Book 39, p. 322 (1998).
11. FROST, J.D. and 13 OTHERS, A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer, 80, 317-333 (1997).
12. GABIZON, A., CATANE, R., UZIELY, B., KAUFMAN, B., SAFRA, T., COHEN, R. and MARTIN, F., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54, 987-992 (1994).
13. HANSEN, C.B., KAO, G.Y., MOASE, E.H., ZALIPSKY, S. and ALLEN, T.M., Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. biophys. Acta, 1239, 133-144 (1995).
14. HONSIK, C.J., JUNG, G. and REISFELD, R.A., LAK cells targeted by monoclonal antibody to the disialoganglioside GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc. nat. Acad. Sci. (Wash.), 83, 7983-7987 (1986).
15. HULTIN, T.A., MEHTA, R.G. and MOON, R.C., Simple high performance liquid chromatographic method for the separation of retinoids including N-(4-hydroxyphenyl)-all-trans-retinamide. J. Chromatogr., 341, 187-192 (1985).
16. HUWYLER, J., DAFANG, W. and PARDRIDGE, W.M., Brain drug delivery of small molecules using immunoliposomes. Proc. nat. Acad. Sci. (Wash.), 93, 14164-14169 (1996).
17. KALEMKERIAN, G.P., SLUSHER, R., RAMALINGAM, S., GADGEEL, S. and MABRY, M., Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J. nat. Cancer Inst., 87, 1674-1680 (1995).
18. KELLOFF, G.J., Chemoprevention Branch and Agent Development Commitee. Division of Cancer Prevention and Control. National Cancer Institute. Clinical development plan: N-(4-hydroxyphenyl)retinamide. J. Cell Biochem. (Suppl.), 20, 176-196 (1994).
19. KETCHAM, A.S. and BALCH, C.M., Classification and staging systems. In: C.M. Balch and G.W. Milton (eds.). Cutaneous melanoma: clinical management and treatment results worldwide, J.B. Lippincott. Philadelphia (1985).
20. KIRPOTIN, D., PARK, J.W., HONG, K., ZALIPSKY, S., LI, W.-L., CARTER, P., BENZ, C.C. and PAPAHADJOPOULOS, D., Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36, 66-75 (1997).
21. LASIC, D.D., Doxorubicin in sterically stabilized liposomes. Nature (Lond.), 380, 561-562 (1996).
22. LEE, R.J. and LOW, P.S., Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. biophys. Acta, 1233, 134-144 (1995).
23. LOPES DE MENEZES, D.E., PILARSKI, L.M. and ALLEN, T.M., In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res., 58, 3320-3330 (1998).
24. LOTAN, R., Retinoids and apoptosis: implications for cancer chemoprevention and therapy (editorial). J. nat. Cancer Inst., 87, 1655-1657 (1995).
25. MARSHALL, E., Cancer warriors claim a victory. Science, 279, 1842-1843 (1998).
26. MUNTALDO, P.G., PAGNAN, G., PASTORINO, F., CHIESA, V., RAFFAGHELLO, L., KIRCHMEIER, M., ALLEN, T.M. and PONZONI, M., N-(4-hydroxyphenyl)retinamide is cytotoxic to melanoma cells in vitro through induction of programed cell death. Int. J. Cancer, 81, 262-267 (1999).
27. MUJOO, K., CHERESH, D.A., YANG, K.M. and REISFELD, R.A., Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res., 47, 1098-1104 (1986).
28. PAGNAN, G., CARIDI, G., MONTALDO, P., BADO, M., CHIESA, V., ALLEN, M.T. and PONZONI, M., Apoptosis of human neuroblastoma cells induced by liposome-encapsulated fenretinide. J. Liposome Res., 8, 401-423 (1998).
29. HER2 immunoliposomes for cancer therapy. Proc. nat. Acad. Sci. (Wash.), 92, 1327-1331 (1995).
30. POLLARD, M., LUCKERT, P.H. and SPORN, M.B., Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res., 51, 3610-3611 (1991).
31. PONZONI, M., BOCCA, P., CHIESA, V., DECENSI, A., PISTOIA, V., RAFFAGHELLO, L., ROZZO, C. and MONTALDO, P.G., Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res., 55, 853-861 (1995).
32. SALEH, M.N., KHAZAELI, M.B., WHELER, R.H., ALLEN, L., TILDEN, A.B., GRIZZLE, W., REISFELD, R.A., YU, A.L., GILLIES, S.D. and LOBUGLIO, A.F., Phase 1 trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum. Antibodies Hybridomas, 3, 19-23 (1992).
33. SCHULZ, G., CHERESH, D.A., VARK, I.N.M., YU, A., STAFFILENO, L.K. and REISFELD, R.A., Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res., 44, 5914-5920 (1984).
34. SPRAGG, D.D., ALFORD, D.R., GREFERATH, R., LARSEN, C.E., LEE, K.-D., GURTNER, G.C., CYBULSKY, M.I., TOSI, P.F., NICOLAU, C. and GIMBRONE, M.A., Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc. nat. Acad Sci. (Wash.), 94, 8795-8800 (1997).
35. SUPINO, R., CROSTI, M., CLERICI, M., WALTERS, A.S., CLERIS, L., ZUNINO, F. and FORMELLI, F., Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int. J. Cancer, 65, 491-497 (1996).
36. SZOKA, F. and PAPAHADJOPOULOS, D., Liposomes: preparation and characterization. In: C.G. Knight (ed.). Liposomes: from physical structure to therapeutic applications, Elsevier/North-Holland, Amsterdam (1991).
37. UTTENREUTHER-FISCHER, M.M., HUANG, C.S. and YU, A.L., Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase 1 trial in neuroblastoma patients. Cancer Immunol. Immunother., 41, 331-338 (1995).
38. WARGALLA, U.C. and REISFELD, R.A., Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc. nat. Acad. Sci. (Wash.), 86, 5146-5150 (1989).
39. WEINSTEIN, J.N. and VAN OSDOL, W., Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier." Cancer Res., 52, 2747-2751 (1992).
40. WU, Z.N., DA, D., RUDOLL, T.L., NEEDHAM, D., WHORTON, A.R. and DEWHIRST, M.W., Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res., 53, 3765-3770 (1993).
41. YUAN, F., LEUNIG, M., HUANG, S.K., BERK, D.A., PAPAHADJOPOULOS, D. and JAIN, R.K., Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 54, 3352-3356 (1994).